Demo Data from EDBT 2026 / reviewers in the wild / expert
Karim Malki
dblp:237/9393
· DBLP profile ↗
3ranked-venue papers
0as first author
0since 2021 · last 2020
0000-0001-7120-3364ORCID · corroborated
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 3
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
3 papers |
Bioinformatics and computational biology · 95% Computational science and engineering · 5% |
Topics — the 6 heaviest of 7, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › transcriptomics › RNA-seq analysis
RNA-seq quality control |
0.4 | 1 | 2020 | RNASeq_similarity_matrix: visually identify sample mix-ups in RNASeq data using a 'genomic' sequence similarity matrix · Bioinform. 2020 |
Bioinformatics and computational biology › epigenomics › DNA methylation
DNA methylation analysis |
0.4 | 1 | 2019 | Bigmelon: tools for analysing large DNA methylation datasets · Bioinform. 2019 |
Bioinformatics and computational biology
drug discovery |
0.4 | 1 | 2019 | TractaViewer: a genome-wide tool for preliminary assessment of therapeutic target druggability · Bioinform. 2019 |
Bioinformatics and computational biology › epigenomics
epigenome-wide association study |
0.4 | 1 | 2019 | Bigmelon: tools for analysing large DNA methylation datasets · Bioinform. 2019 |
Bioinformatics and computational biology
epigenomics |
0.4 | 1 | 2019 | Bigmelon: tools for analysing large DNA methylation datasets · Bioinform. 2019 |
Computational science and engineering
high-dimensional data analysis |
0.1 | 1 | 2019 | Bigmelon: tools for analysing large DNA methylation datasets · Bioinform. 2019 |
Methods — techniques the papers use, named apart from their topics
sequence similarity matrix · 0.4gdsfmt · 0.4data integration · 0.4corearray genomic data structure · 0.4
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2020 | RNASeq_similarity_matrix: visually identify sample mix-ups in RNASeq data using a 'genomic' sequence similarity matrixabstractMOTIVATION: Mistakes in linking a patient's biological samples with their phenotype data can confound RNA-Seq studies. The current method for avoiding such sample mixups is to test for inconsistencies between biological data and known phenotype data such as sex. However, in DNA studies a common QC step is to check for unexpected relatedness between samples. Here, we extend this method to RNA-Seq, which allows the detection of duplicated samples without relying on identifying inconsistencies with phenotype data. SUMMARY: We present RNASeq_similarity_matrix: an automated tool to generate a sequence similarity matrix from RNA-Seq data, which can be used to visually identify sample mix-ups. This is particularly useful when a study contains multiple samples from the same individual, but can also detect contamination in studies with only one sample per individual. AVAILABILITY: RNASeq_similarity_matrix has been made available as a documented GPL licensed Docker image on www.github.com/nicokist/RNASeq_similarity_matrix. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Nicolaas C. Kist, Robert A. Power, Andrew Skelton, Seth D. Seegobin, Moira Verbelen, Bushan K. Bonde, Karim Malki |
Bioinform. | 7 |
| 2019 | Bigmelon: tools for analysing large DNA methylation datasetsabstractMOTIVATION: The datasets generated by DNA methylation analyses are getting bigger. With the release of the HumanMethylationEPIC micro-array and datasets containing thousands of samples, analyses of these large datasets using R are becoming impractical due to large memory requirements. As a result there is an increasing need for computationally efficient methodologies to perform meaningful analysis on high dimensional data. RESULTS: Here we introduce the bigmelon R package, which provides a memory efficient workflow that enables users to perform the complex, large scale analyses required in epigenome wide association studies (EWAS) without the need for large RAM. Building on top of the CoreArray Genomic Data Structure file format and libraries packaged in the gdsfmt package, we provide a practical workflow that facilitates the reading-in, preprocessing, quality control and statistical analysis of DNA methylation data.We demonstrate the capabilities of the bigmelon package using a large dataset consisting of 1193 human blood samples from the Understanding Society: UK Household Longitudinal Study, assayed on the EPIC micro-array platform. AVAILABILITY AND IMPLEMENTATION: The bigmelon package is available on Bioconductor (http://bioconductor.org/packages/bigmelon/). The Understanding Society dataset is available at https://www.understandingsociety.ac.uk/about/health/data upon request. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Tyler J. Gorrie-Stone, Melissa C. Smart, Ayden Saffari, Karim Malki, Eilis J. Hannon, Joe Burrage, Jonathan Mill, Meena Kumari, Leonard C. Schalkwyk |
Bioinform. | 4 |
| 2019 | TractaViewer: a genome-wide tool for preliminary assessment of therapeutic target druggabilityabstractSUMMARY: We present software to characterize and rank potential therapeutic (drug) targets with data from public databases and present it in a user-friendly format. By understanding potential obstacles to drug development through the gathering and understanding of this information, combined with robust approaches to target validation to generate therapeutic hypotheses, this approach may provide high quality targets, leading the process of drug development to become more efficient and cost-effective. AVAILABILITY AND IMPLEMENTATION: The information we gather on potential targets concerns small-molecule druggability (ligandability), suitability for large-molecule approaches (e.g. antibodies) or new modalities (e.g. antisense oligonucleotides, siRNA or PROTAC), feasibility (availability of resources such as assays and biological knowledge) and potential safety risks (adverse tissue-wise expression, deleterious phenotypes). This information can be termed 'tractability'. We provide visualization tools to understand its components. TractaViewer is available from https://github.com/NeilPearson-Lilly/TractaViewer. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Neil Pearson, Karim Malki, Lewis Vidler, Cara Ruble, James Scherschel, Brian Eastwood, David A. Collier |
Bioinform. | 2 |